tirzepatide weight loss effectiveness compared to semaglutide In adults with obesity but not diabetes, leads significantly greater than over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Semaglutide vs Tirzepatide for Weight

Serious risks and warnings Boxed warning: thyroid C-cell tumors Rodent studies showed dose-dependent C-cell tumors

[T]he promotion and advertising of these compounded drugs is subject to FDA regulation

and certain disease states (see Primary systemic carnitine deficiency) (12)

Semaglutide is a GLP-1 receptor agonist licensed for type 2 diabetes and weight management in the UK No direct mechanism exists linking semaglutide to reduced oestrogen production at the ovarian level Weight loss decreases adipose tissue containing aromatase enzyme, potentially reducing peripheral oestrogen conversion, particularly in postmenopausal women Semaglutide does not affect oral contraceptive efficacy and should be discontinued at least two months before planned pregnancy Women experiencing menstrual irregularities or severe menopausal symptoms during treatment should seek medical advice for appropriate investigation Table of Contents Understanding Ozempic and Hormonal Effects Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses under the brand name Wegovy, for weight management in adults with obesity or overweight with weight-related comorbidities